Similar articles for PMID: 26660725

Year	Number of Results
1949	1
1979	1
1991	1
1999	3
2001	1
2002	3
2003	1
2004	3
2005	4
2006	3
2007	4
2008	7
2009	11
2010	10
2011	14
2012	16
2013	19
2014	35
2015	47
2016	58
2017	34
2018	35
2019	39
2020	50
2021	54
2022	22
2023	12
2024	0

1

Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.

Magnusson LU, Hagberg Thulin M, Plas P, Olsson A, Damber JE, Welén K. Magnusson LU, et al. Prostate. 2016 Mar;76(4):383-93. doi: 10.1002/pros.23133. Epub 2015 Dec 10. Prostate. 2016. PMID: 26660725

2

Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050).

Jennbacken K, Welén K, Olsson A, Axelsson B, Törngren M, Damber JE, Leanderson T. Jennbacken K, et al. Prostate. 2012 Jun 1;72(8):913-24. doi: 10.1002/pros.21495. Epub 2011 Oct 5. Prostate. 2012. PMID: 22287276

3

The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts.

Dalrymple SL, Becker RE, Isaacs JT. Dalrymple SL, et al. Prostate. 2007 May 15;67(7):790-7. doi: 10.1002/pros.20573. Prostate. 2007. PMID: 17373719

4

[Tasquinimod: How to act on microenvironment in metastatic prostate cancer].

Houédé N, Irani J. Houédé N, et al. Prog Urol. 2015 May;25(6):298-305. doi: 10.1016/j.purol.2015.01.008. Epub 2015 Feb 13. Prog Urol. 2015. PMID: 25684391 Review. French.

5

Upregulation of CRMP4, a new prostate cancer metastasis suppressor gene, inhibits tumor growth in a nude mouse intratibial injection model.

Zhou W, Xie P, Pang M, Yang B, Fang Y, Shu T, Liu C, Wang X, Zhang L, Li S, Rong L. Zhou W, et al. Int J Oncol. 2015 Jan;46(1):290-8. doi: 10.3892/ijo.2014.2705. Epub 2014 Oct 10. Int J Oncol. 2015. PMID: 25338524

6

Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment.

Isaacs JT, Dalrymple SL, Rosen DM, Hammers H, Olsson A, Leanderson T. Isaacs JT, et al. Oncotarget. 2014 Sep 30;5(18):8093-106. doi: 10.18632/oncotarget.2378. Oncotarget. 2014. PMID: 25193858 Free PMC article.

7

The anti-tumor effect of the quinoline-3-carboxamide tasquinimod: blockade of recruitment of CD11b(+) Ly6C(hi) cells to tumor tissue reduces tumor growth.

Deronic A, Tahvili S, Leanderson T, Ivars F. Deronic A, et al. BMC Cancer. 2016 Jul 11;16:440. doi: 10.1186/s12885-016-2481-0. BMC Cancer. 2016. PMID: 27400708 Free PMC article.

8

Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors.

Olsson A, Björk A, Vallon-Christersson J, Isaacs JT, Leanderson T. Olsson A, et al. Mol Cancer. 2010 May 17;9:107. doi: 10.1186/1476-4598-9-107. Mol Cancer. 2010. PMID: 20470445 Free PMC article.

9

Osteoblasts are "educated" by crosstalk with metastatic breast cancer cells in the bone tumor microenvironment.

Kolb AD, Shupp AB, Mukhopadhyay D, Marini FC, Bussard KM. Kolb AD, et al. Breast Cancer Res. 2019 Feb 27;21(1):31. doi: 10.1186/s13058-019-1117-0. Breast Cancer Res. 2019. PMID: 30813947 Free PMC article.

10

Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer.

Armstrong AJ, Häggman M, Stadler WM, Gingrich JR, Assikis V, Polikoff J, Damber JE, Belkoff L, Nordle Ö, Forsberg G, Carducci MA, Pili R. Armstrong AJ, et al. Clin Cancer Res. 2013 Dec 15;19(24):6891-901. doi: 10.1158/1078-0432.CCR-13-1581. Epub 2013 Nov 19. Clin Cancer Res. 2013. PMID: 24255071 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

429 results

Results by year